TransGenic Group

TransGenic Group FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of TransGenic Group (2342.T) as of Nov 11, 2026 is 55.07 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 7.47 % — a change of 637.59% (higher).

FCF Conversion

55.07 %

YoY

637.59%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of TransGenic Group is 2026 55.07 % . FCF Conversion Rate (FCF/EBITDA) of TransGenic Group was 2025 7.47 % . It decreases by 637.59% higher compared to the previous year.

The TransGenic Group FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
-85.45 JPY
Jan 1, 2020
63.01 JPY
Jan 1, 2021
197.07 JPY
Jan 1, 2022
67.00 JPY
Jan 1, 2023
423.83 JPY
Jan 1, 2024
-16,110.67 JPY
Jan 1, 2025
7.47 JPY
Jan 1, 2026
55.07 JPY
The TransGenic Group FCF Conversion history
YEARFCF ConversionYoY
55.07 %+637.59%
7.47 %-100.05%
-16,110.67 %-3,901.19%
423.83 %+532.58%
67.00 %-66.00%
197.07 %+212.76%
63.01 %-173.74%
-85.45 %-112.32%
693.68 %+429.48%
131.01 %-83.90%
813.91 %+152.14%
322.80 %+49.50%
215.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

FCF Conversion Rate (FCF/EBITDA) of TransGenic Group is 55.07 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of TransGenic Group changed from 7.47 % to 55.07 %, representing a 637.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s TransGenic Group with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — TransGenic Group

All Key Metrics — TransGenic Group